Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Assembly Biosciences (ASMB) EBITDA Margin (2017 - 2025)

Assembly Biosciences (ASMB) has 8 years of EBITDA Margin data on record, last reported at 83.48% in Q3 2025.

  • For Q3 2025, EBITDA Margin rose 5495.0% year-over-year to 83.48%; the TTM value through Sep 2025 reached 103.47%, up 4016.0%, while the annual FY2024 figure was 141.33%, 70337.0% up from the prior year.
  • EBITDA Margin reached 83.48% in Q3 2025 per ASMB's latest filing, up from 106.21% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 83.48% in Q3 2025 and bottomed at 300.9% in Q3 2021.
  • Average EBITDA Margin over 4 years is 145.07%, with a median of 138.44% recorded in 2024.
  • Peak YoY movement for EBITDA Margin: plummeted -29046bps in 2021, then skyrocketed 6557bps in 2025.
  • A 4-year view of EBITDA Margin shows it stood at 300.9% in 2021, then skyrocketed by 50bps to 150.33% in 2023, then grew by 6bps to 141.23% in 2024, then skyrocketed by 41bps to 83.48% in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA Margin were 83.48% in Q3 2025, 106.21% in Q2 2025, and 94.07% in Q1 2025.